Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Present at Guggenheim 3rd Annual Neuro/Immunology Conference

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
November 04, 2021 07:00 ET | Source: Passage Bio

Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights

On track to report initial safety and 30-day biomarker data for cohort 1 from Imagine-1 global Phase 1/2 trial for PBGM01 for the treatment of infantile GM1 in 4Q21Activated multiple clinical sites...
October 28, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Report Third Quarter 2021 Financial Results on November 4, 2021

PHILADELPHIA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
September 27, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Participate in Upcoming October Conferences

PHILADELPHIA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for central nervous system (CNS)...
September 17, 2021 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
September 07, 2021 07:00 ET | Source: Passage Bio

Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors

PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
September 02, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference

PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
August 27, 2021 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
August 05, 2021 07:00 ET | Source: Passage Bio

Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights

Expanded strategic collaboration with University of Pennsylvania’s Gene Therapy Program to advance genetic medicines for large CNS diseases, initially focused on Alzheimer’s Disease and Temporal Lobe...
August 04, 2021 21:00 ET | Source: Passage Bio

Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.

PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...